chr16-2084477-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000548.5(TSC2):c.4255C>T(p.Gln1419*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000548.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
Tuberous sclerosis syndrome Pathogenic:1Other:1
PVS1,PS4_Moderate -
- -
Tuberous sclerosis 2 Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln1419*) in the TSC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with tuberous sclerosis complex (PMID: 10205261). ClinVar contains an entry for this variant (Variation ID: 49821). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
Nonsense variant predicted to result in nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 25525159, 10205261, 10090883, 12111193, 15121797, 17304050, 28065512) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q1419* variant (also known as c.4255C>T), located in coding exon 33 of the TSC2 gene, results from a C to T substitution at nucleotide position 4255. This changes the amino acid from a glutamine to a stop codon within coding exon 33. This mutation had been detected in multiple individuals meeting diagnostic criteria for tuberous sclerosis complex (TSC) (Jones AC et al. Am. J. Hum. Genet., 1999 May;64:1305-15; Cai Y et al. Urology, 2017 Jan; Roberts PS et al. J. Med. Genet., 2004 May;41:e69). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at